Study Objective: 

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.

​

Key Requirements:

>6 years old - <18 years old ​

​

Study Information: ​

  • Compensation for time and travel up to 

  • Transportation can be arranged at no cost to you 

  • Study related exams at to cost

​

Location:

  • TOPAZ Clinical Research 2513 E. Semoran Blvd Apopka, FL 32703

 


Pediatric Migraine